A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

Inclusion criteria for non-hemophilia participants: Panel A \- Male or female between 65 to 85 years of age Panel B \- Male between 18 to 45 years of age Both Panels * Weight of ≥50 kg and ≤110 kg * In good health * No clinically significant abnormality on electrocardiogram (ECG) * Nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months Exclusion criteria for non-hemophilia participants: * History of stroke, chronic seizures, or major neurological disorder * History of clinically significant endocrine, gastrointestinal (including peptic ulcer disease), cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * History of malignant neoplastic disease, with the exception of adequately treated non-melanomatous skin carcinoma or other malignancies that have been successfully treated ≥10 years prior to the study * History of a thrombotic or platelet-related disorder including prior deep venous thrombosis or pulmonary embolus * Use of warfarin, coumadin, heparin, aspirin, dabigatran etexilate, rivaroxaban or dipyridamole within 2 weeks * History of poor wound healing * Unable to refrain from or anticipates the use of any medication, including aspirin and aspirin-containing products, all non-steroidal anti-inflammatory drug (NSAID)-containing products (including pain, cold and allergy products, etc.) and including prescription and non-prescription drugs or herbal remedies (such as St. John's Wort \[Hypericum perforatum\]) beginning approximately 2 weeks (or 5 half-lives) prior to initiation of the treatment periods, throughout the study until the post-study visit * Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 mL/10 ounces\], wine \[125 mL/4 ounces\], or distilled spirits \[25 mL/1 ounce\]) per day * Consumption of excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day * Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) or participation in another investigational study within 4 weeks * History of significant multiple and/or severe allergies (including latex allergy), or an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food, including dabigatran etexilate and rivaroxaban * Current regular user (including illicit drugs or has a history of drug \[including alcohol\] abuse within approximately 6 months * History (including family history if hereditary) or symptoms of clinically relevant bleeding disorder * Organic lesion at risk of bleeding (e.g., aneurysm, cavernous hemangioma, arterio-venous malformation) * History of frequent epistaxis or has recurrent or active gingivitis or hemorrhoids Inclusion criteria for hemophilia participants: * Male with diagnosis of hemophilia B between 18 to 64 years of age * Weight of ≥110 lbs and ≤300 lbs * Has not received clotting factor in the 7 days prior to blood sampling * No active bleeding event * No procedure or surgery in the past 8 weeks * Judged to be in good health based on medical history * Has not smoked more than 2 cigarettes per day for at least approximately 1 week prior; has not smoked a pipe or cigar or chewed tobacco for at least 3 days prior * Can refrain from the use of all NSAIDs (e.g., Advil, Aleve, aspirin), all NSAID-containing products (including pain, cold, and allergy products, etc.), herbal meds or drugs for 7 days prior to the date of study procedure Exclusion criteria for hemophilia participants: * Clinically significant endocrine, gastrointestinal (including peptic ulcer disease), cardiovascular, hematological (except factor IX deficiency), immunological, renal, respiratory, neurological or genitourinary abnormalities or diseases * History of malignant neoplastic disease, with the exception of adequately treated non-melanomatous skin carcinoma or other malignancies that have been successfully treated ≥10 years prior to the study * Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 mL/10 ounces\], wine \[125 mL/4 ounces\], or distilled spirits \[25 mL/1 ounce\]) within 24 hours prior to study procedures * Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) or participation in another investigational study within 7 days prior to the date of study procedures * Current regular user (including illicit drugs or has a history of drug \[including alcohol\] abuse within approximately 6 months